 I'm Nicole Murray with your Money Now. The FDA has approved Eli Lilly's Alzheimer's drug, Denonimab, expanding the limited treatment options for the mind-wasting disease. The agency approved the treatment, which will be sold under the brand name Kisunla, for adults in early stages of the disease. Nearly 7 million Americans have the condition, and it is the fifth leading cause of death for adults over 65.